Revisiting AMPA Receptors as an Antiepileptic Drug Target

  title={Revisiting AMPA Receptors as an Antiepileptic Drug Target},
  author={Michael A. Rogawski},
  journal={Epilepsy Currents},
  pages={56 - 63}
  • M. Rogawski
  • Published 1 March 2011
  • Biology, Psychology, Medicine
  • Epilepsy Currents
In the 1990s there was intense interest in ionotropic glutamate receptors as therapeutic targets for diverse neurological disorders, including epilepsy. NMDA receptors were thought to play a key role in the generation of seizures, leading to clinical studies of NMDA receptor blocking drugs in epilepsy. Disappointing results dampened enthusiasm for ionotropic glutamate receptors as a therapeutic target. Eventually it became appreciated that another type of ionotropic glutamate receptor, the AMPA… 

AMPA receptors as drug targets in neurological disease – advantages, caveats, and future outlook

Most excitatory transmission in the brain is mediated by the AMPA receptor subtype of the ionotropic glutamate receptors. In many neurological diseases, synapse structure and AMPA receptor function

AMPA receptors and perampanel behind selected epilepsies: current evidence and future perspectives

The role of AMPA receptors in the neuronal hyperexcitability underlying epilepsy, the mechanism of action and clinical experience on the anti-seizure activity of perampanel, and the rationale for targeting AMPA receptor in specific epileptic disorders are evaluated.

AMPA Receptors as Therapeutic Targets for Neurological Disorders.

New AMPA antagonists in epilepsy

The development of AMPAR antagonists confirms their great clinical potential and their arrival to clinical practice has been slowed down by their unfavorable pharmacokinetic profile and tolerability; however, their clinical use might be justified by their efficacy and the new drugs developed such as perampanel have been greatly ameliorated from both points of view.

The AMPA receptor antagonist perampanel is a new hope in the treatment for epilepsy

The data raised from the studies can give a hope that perampanel offers a valuable option as an adjuvant therapy for pharmacoresistant partial-onset and secondarily generalized seizures.

The AMPA receptor antagonist perampanel is a new hope in the treatment for epilepsy

The data raised from the studies can give a hope that perampanel offers a valuable option as an adjuvant therapy for pharmacoresistant partial‐onset and secondarily generalized seizures.

Research advances in basic mechanisms of seizures and antiepileptic drug action.

The AMPA receptor antagonist perampanel in the adjunctive treatment of partial-onset seizures: clinical trial evidence and experience

  • B. Steinhoff
  • Medicine, Psychology
    Therapeutic advances in neurological disorders
  • 2015
Perampanel is the first-in-class orally active, selective, noncompetitive antagonist of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors and the pharmacokinetic profile offers once-daily dosing in the evening as the best route of administration.



AMPA receptor antagonists for the treatment of stroke.

  • T. Weiser
  • Biology
    Current drug targets. CNS and neurological disorders
  • 2005
Targetting more than one mechanism in the excitotoxicity cascade might be a fruitful approach for the development of neuroprotective drugs.

Kainate receptors in epilepsy and excitotoxicity

Low affinity channel blocking (uncompetitive) NMDA receptor antagonists as therapeutic agents – toward an understanding of their favorable tolerability

Current research attempting to explain the improved tolerability of low affinity NMDA receptor antagonists is reviewed, finding kinetic properties, particularly rapid blocking rate, seem to be of key importance.

Stargazin modulates AMPA receptor antagonism

Therapeutic potential of excitatory amino acid antagonists: channel blockers and 2,3-benzodiazepines.

  • M. Rogawski
  • Biology, Psychology
    Trends in pharmacological sciences
  • 1993

The glutamate story

Development of antagonists binding to specific protein subunits is currently enabling precise identification of discrete iGlu or mGlu receptor subtypes that participate in a range of central synaptic processes, including synaptic plasticity.

2,3-benzodiazepine AMPA antagonists.

In vitro and in vivo pharmacological results with 2,3-benzodiazepine AMPA antagonists indicate their potential therapeutical value in treating a great variety of central nervous system diseases, of which epilepsy and neurodegenerative disorders are regarded as the most important.

The involvement of excitatory amino acids in neocortical epileptogenesis: NMDA and non-NMDA receptors

The activation of non-NMDA receptors is necessary and sufficient to induce epileptiform activity in the neocortical slices when the GABAergic inhibitory mechanism is compromised, and their partial involvement in the PDS is dependent upon the integrity of the non- NMDA mediated input.

Treatment of early and late kainic acid‐induced status epilepticus with the noncompetitive AMPA receptor antagonist GYKI 52466

The ability of the noncompetitive AMPA receptor antagonist GYKI 52466 to protect against kainic acid–induced status epilepticus in mice is assessed.